Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
By Thomas L. Chenevert, L. D. Stegman, J. M. Taylor, P. Robertson, H. Greenberg, A. Rehemtulla, B. Ross. Journal of the National Cancer Institute, 2000
707 citations recorded by the source corpus.
Subfields: Genetics, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/0ba67c6ae4fc6c14591062f640a6af60af872348
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma (2011, background): “Diffusion-weighted imaging may have an additional role in assessing changes in cellularity induced by the treatment (32, 33), provided that the causative factors (invasive cells, necrosis, edema) can be distinguished.”
- Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. (2009, background): “Diffusion-weighted MRI has also been investigated as a biomarker of response to treatment in brain tumors, with increased diffusion values detected shortly after treatment initiation suggesting a favorable outcome [42,54,55].”
- Imaging and cancer: A review (2008, background): “The observed increase in water ADC following therapy is directly related to the number of cells killed and is thought to be due to the liberation of water into the extracellular space as a result of cell necrosis (Chenevert et al., 2000).”